164 related articles for article (PubMed ID: 27620481)
21. Activity of new macrolides against Bordetella pertussis and Bordetella parapertussis.
Hoppe JE; Eichhorn A
Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):653-4. PubMed ID: 2550234
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity of solithromycin against clinical isolates of Legionella pneumophila serogroup 1.
Mallegol J; Fernandes P; Melano RG; Guyard C
Antimicrob Agents Chemother; 2014; 58(2):909-15. PubMed ID: 24277019
[TBL] [Abstract][Full Text] [Related]
23. Solithromycin (CEM-101): A New Fluoroketolide Antibiotic and Its Role in the Treatment of Gonorrhea.
Mancuso AM; Gandhi MA; Slish J
J Pharm Pract; 2018 Apr; 31(2):195-201. PubMed ID: 28490220
[TBL] [Abstract][Full Text] [Related]
24. The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis.
Brett M; Short P; Beatson S
J Antimicrob Chemother; 1998 Mar; 41 Suppl B():23-7. PubMed ID: 9579709
[TBL] [Abstract][Full Text] [Related]
25. Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada.
Marchand-Austin A; Memari N; Patel SN; Tang P; Deeks SL; Jamieson FB; Crowcroft NS; Farrell DJ
Int J Antimicrob Agents; 2014 Jul; 44(1):82-4. PubMed ID: 24837412
[No Abstract] [Full Text] [Related]
26. In vitro activity of the new fluoroketolide solithromycin (CEM-101) against a large collection of clinical Neisseria gonorrhoeae isolates and international reference strains, including those with high-level antimicrobial resistance: potential treatment option for gonorrhea?
Golparian D; Fernandes P; Ohnishi M; Jensen JS; Unemo M
Antimicrob Agents Chemother; 2012 May; 56(5):2739-42. PubMed ID: 22354296
[TBL] [Abstract][Full Text] [Related]
27. Minimum inhibitory concentrations of erythromycin and other antibiotics for Czech strains of Bordetella pertussis.
Jakubů V; Zavadilová J; Fabiánová K; Urbášková P
Epidemiol Mikrobiol Imunol; 2015 Mar; 64(1):12-5. PubMed ID: 25872990
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial susceptibility testing of historical and recent clinical isolates of Bordetella pertussis in the United Kingdom using the Etest method.
Fry NK; Duncan J; Vaghji L; George RC; Harrison TG
Eur J Clin Microbiol Infect Dis; 2010 Sep; 29(9):1183-5. PubMed ID: 20521155
[TBL] [Abstract][Full Text] [Related]
29. [Pertussis (Whooping cough)--an update].
Stock I
Med Monatsschr Pharm; 2015 Dec; 38(12):484-8. PubMed ID: 26837155
[TBL] [Abstract][Full Text] [Related]
30. Solithromycin for the treatment of community-acquired bacterial pneumonia.
Viasus D; Ramos O; Ramos L; Simonetti AF; Carratalà J
Expert Rev Respir Med; 2017 Jan; 11(1):5-12. PubMed ID: 27753516
[TBL] [Abstract][Full Text] [Related]
31. Determination of Disk Diffusion and MIC Quality Control Guidelines for Solithromycin, a Novel Fluoroketolide Antibacterial, against Neisseria gonorrhoeae.
Riedel S; Ross JE; Farrell DJ; Flamm RK; Jones RN
J Clin Microbiol; 2015 Dec; 53(12):3888-90. PubMed ID: 26378286
[TBL] [Abstract][Full Text] [Related]
32. Effect of Macrolides and β-lactams on Clearance of Bordetella pertussis in the Nasopharynx in Children With Whooping Cough.
Mi YM; Hua CZ; Fang C; Liu JJ; Xie YP; Lin LN; Wang GL
Pediatr Infect Dis J; 2021 Feb; 40(2):87-90. PubMed ID: 33021592
[TBL] [Abstract][Full Text] [Related]
33. Pharmacotherapy for Bordetella pertussis infection. II. A synthesis of clinical sciences.
Cimolai N
Int J Antimicrob Agents; 2021 Mar; 57(3):106257. PubMed ID: 33310117
[TBL] [Abstract][Full Text] [Related]
34. Whooping Cough in Adults: A Series of Severe Cases.
Zycinska K; Cieplak M; Chmielewska M; Nitsch-Osuch A; Klaczkow A; Hadzik-Blaszczyk M; Kur Z; Wardyn KA
Adv Exp Med Biol; 2017; 955():47-50. PubMed ID: 28039663
[TBL] [Abstract][Full Text] [Related]
35. Antimicrobial susceptibility of Bordetella pertussis isolates in the state of Washington.
Galanakis E; Englund JA; Abe P; Qin X
Int J Antimicrob Agents; 2007 May; 29(5):609-11. PubMed ID: 17344029
[No Abstract] [Full Text] [Related]
36. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition.
Kobayashi Y; Wada H; Rossios C; Takagi D; Higaki M; Mikura S; Goto H; Barnes PJ; Ito K
J Pharmacol Exp Ther; 2013 Apr; 345(1):76-84. PubMed ID: 23359665
[TBL] [Abstract][Full Text] [Related]
37. The role of solithromycin in the management of bacterial community-acquired pneumonia.
Van Bambeke F; Tulkens PM
Expert Rev Anti Infect Ther; 2016; 14(3):311-24. PubMed ID: 26848612
[TBL] [Abstract][Full Text] [Related]
38. Bordetella pertussis isolates with a heterogeneous phenotype for erythromycin resistance.
Wilson KE; Cassiday PK; Popovic T; Sanden GN
J Clin Microbiol; 2002 Aug; 40(8):2942-4. PubMed ID: 12149356
[TBL] [Abstract][Full Text] [Related]
39. Appearance of macrolide-resistant Bordetella pertussis strains in China.
Wang Z; Li Y; Hou T; Liu X; Liu Y; Yu T; Chen Z; Gao Y; Li H; He Q
Antimicrob Agents Chemother; 2013 Oct; 57(10):5193-4. PubMed ID: 23877687
[No Abstract] [Full Text] [Related]
40. [Epidemiological surveillance of Bordetella pertussis and parapertussis sensitivity to antibiotics].
Janovská D; Výmola F
Cesk Epidemiol Mikrobiol Imunol; 1971 Jul; 20(4):184-8. PubMed ID: 4328643
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
